VIP会员
| 中文名: | 雷诺嗪;N-(2,6-二甲基苯基)-2-(4-(2-羟基-3-(2-甲氧基苯氧基)丙基)哌嗪-1-基)乙酰胺 |
| 中文别名: | 雷诺嗪; N-(2,6-二甲基苯基)-4-[2-羟基-3-(2-甲氧苯氧基)丙基]-1-哌嗪乙酰胺;Ranexa; CVT 303; RS 43285-003 |
| 英文名称： | Ranolazine |
| 英文别名： | N-(2,6-Dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide |
| CAS No.: | 95635-55-5 |
| 分子式: | C24H33N3O4 |
| 分子量: | 427.54 |
| 性状: | 属性溶解性DMSO 86 mg/mLWater<1 mg/mL Ethanol 20 mg/mL描述产品介绍Ranolazine 是一种抗心绞痛药物。用途An anti-ischemic agent which inhibits late sodium currents.生化机理Ranolazine is an anti-ischemic compound, which inhibits late sodium current that results in a reduction of Na+ dependent Ca2+ overload. Studies indicate that ATP production is shifted towards glucose oxidation by Ranolazine. This is due to the fact that more oxygen is required to phosphorylate the same amount of ATP during fatty acid oxidation than carbohydrate oxidation. These studies indicate that Ranolazine also inhibits oxygen consumption and ketogenesis by fatty acids in liver cells.包装R129868-100mg,R129868-500mg in glass bottle |
| 储存: | |
| 安全术语: | |
| 风险术语: | |
| 危险品标志: | |
| 危险品运输编号: | |
| 用途: | Ranolazine(Ranexa) is an antianginal medication. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia in rabbits. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia in rats. [1] |
粤公网安备44196802000105号
400-6226-992